Maravai LifeSciences Holdings, Inc. - Class A common stock (MRVI)

This medical device firm supplies hospitals worldwide with single-use products for critical care, surgery, and interventional procedures.

This energy sector distributor delivers maintenance, repair, and supply chain solutions to industrial clients across a global network.

Arcutis Biotherapeutics develops topical therapies for chronic skin conditions, with a portfolio targeting psoriasis and atopic dermatitis.

Maravai LifeSciences (MRVI) stock fell after Q3 2025 revenue missed estimates. The company reported a net loss and provided full-year guidance below analyst expectations.

Today, August 11, 2025, marks a significant day for investors looking beyond the typical S&P 500 giants, as a diverse array of companies across various sectors unveiled their latest quarterly earnings. These reports, ranging from cybersecurity and fintech to mining and life sciences, offer a crucial granular view into

MRVI earnings call for the period ending December 31, 2024.

MRVI earnings call for the period ending September 30, 2024.